Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study

Minerva Gastroenterologica e Dietologica

Volumn 49, Issue 1, 2003, Pages 53-62

  Loguercio, C ^a,c   Federico, A ^a   De Girolamo, V ^a   Ferrieri, A ^b   Del Vecchio Blanco, C ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Alfa Wassermann SpA   (Italy)

^c NONE   (Italy)

Author keywords

Cirrhosis, liver; Hepatic encephalopathy, therapy; Rifaximin

Indexed keywords

AMMONIA; LACTITOL; METRONIDAZOLE; NEOMYCIN; PAROMOMYCIN; PLACEBO; RIFAXIMIN; SORBITOL; VANCOMYCIN;

ADULT; AGED; AMMONIA BLOOD LEVEL; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLAPPING TREMOR; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037367384     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jalan R, Seery JP, Taylor-Robinson SP. Pathogenesis and treatment of chronic hepatic encephalopathy. Aliment Pharmacol Ther 1996;10:681-97.
2. Albrecht J, Jones EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neurol Sci 1999;170:138-46.
3. Hazell AS, Butterworth RF. Hepatic encephalopathy: an update of pathophysiologic mechanisms. Proc Soc Exp Biol Med 1999;35:363-9.
4. Butterworth RF. Complications of cirrhosis III. Hepatic encephalopathy. J Hepatol 2000;32:171-80.
5. Mendehal CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH et al. Oxandrolone with oral nutritional support increases survival in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993;17:564-76.
6. Menon KV, Kamath PS. Managing the complications of cirrhosis. Mayo Clin Proc 2000;75:501-9.
7. Jalan R, Turjanski N, Taylor-Robinson SD, Koepp MJ, Richardson MP, Wilson JA et al. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut 2000;46:546-52.
8. Brown H, Trey C, Mc Dermott WV. Lactulose treatment of hepatic encephalopathy in outpatients. Surgery 1971;102:25-7.
9. Morgan MY. The treatment of chronic hepatic encephalopathy. Hepatogastroenterology 1991;38:377-87.
10. Loguercio C, Rinaldi M, Abbiati R, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effect of Enterococcus Faecium SF 68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995;22:351-8.
11. Masini A, Efrati C, Merli M, Attili AF, Amodio P, Ceccanti M et al. Effect of lactitol on blood ammonia response to oral glutammine challenge in cirrhotic patients: evidence for an effect of nonabsorbable disaccharides on small intestine ammonia generation. Am J Gastroenterol 1999;94:3323-7.
12. Tromm A, Griga T, Greving I, Hilden H, Huppe D, Schwegler U et al. Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepatogastroenterology 2000;47:473-7.
13. Shimamoto C, Hirata I, Katsu K. Breath and blood ammonia in liver cirrhosis. Hepatogastroenterology 2000;47:443-5.
14. Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of double-blind crossover trial. Dig Dis Sci 1991;36:1204-8.
15. Cadranel JF, el Younsi M, Pidoux B, Zylberberg P, Benhamou Y, Valla D et al. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol 1995;7:325-9.
16. Celik T, Uzbay T, Cinar K, Bozkaya H, Uzunalimoglu O, Yurdaydin C. Combination treatment of hepatic encephalopathy due to thioacetamide-induced fulminant hepatic failure in the rat with benzodiazepine and opioid receptor antagonists. J Hepatol 1999;31:880-6.
17. Wahren J, Denis J, Desurmont P, Eriksson LS, Escoffier JM, Gauthier HP et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology 1983;3:475-80.
18. Tarao K, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990;31:702-6.
19. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-8.
20. Festi D, Mazzella G, Parini P, Ronchi M, Cipolla A, Orsini M et al. Treatment of hepatic encephalopathy with non-absorbable antibiotics. Ital J Gastroenterol 1992;24:14-6.
21. Gillis JC, Brogden RN. Rifaximin. A review of its anti-bacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-84.
22. Williams R, James OF, Wames TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-8.
23. Rodgers JB, Kiley JE, Balint JA. Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol. Am J Gastroenterol 1973;60:459-65.
24. Mc Clain CJ, Kromhout JP, Zieve L, Duane WC. Effect of sorbitol on psychomotor function. Arch Intern Med 1981;141:901-3.
25. Beavin J, Bjorneklett A, Jenssen E, Blomhoff JP. Pulmonary hydrogen and methane and plasma ammonia after the administration of lactulose or sorbitol. Scand J Gastroenterol 1983;18:343-7.
26. Conn HO. Assessment of the severity of hepatic encephalopathy. In: Rodes J, Arroyo V editors. Therapy in liver disease. Barcelona: Ediciones Doyma SA; 1992.p.277-91.
27. Loguercio C, Del Vecchio Blanco C, Coltorti M. Psychometric tests and latent portal-systemic encephalopathy. Br J Clin Pract 1984;38:407-11.
28. Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, cross-over study. J Hepatol 1987;4:236-44.
29. Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992;15:222-8.
30. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-9.
31. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portalsystemic encephalopathy: a controlled double-blind trial. Dig Dis Sci 1978;23:398-406.
32. Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal systemic encephalopathy: a double-blind, randomized trial. N Engl J Med 1969;281:408-12.
33. Conn HO, Floch MH. Effects of lactulose and lactobacillus acidophylus on the fecal flora. Am J Clin Nutr 1970;23:1588-94.
34. Glodin BR. Health benefits of probiotics. Br J Nutr 1998;80:S203-7.
35. Venturini AP, Marchi E, Blandino G, Mattina R. In vitro and in vivo evaluation of L/105, a new non-absorbable rifamycin. Drug Exp Clin Res 1984;10:691-6.
36. Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11:387-92.
37. Morgan TR, Moritz TE, Mendenhall CL, Haas R and Cooperative Study Group 275. Protein consumption and hepatic encephalopathy in alcoholic hepatitis. J Am Coll Nutr 1995;14:152-8.
38. Merli M, Riggio O, Dally L and Policentrica Italiana Nutrizione Cirrosi. Does malnutrition affect survival in cirrhosis? Hepatology 1996;23:1041-6.
39. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890-5.